Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

Autor: Vicente Vicente, María Isabel Orts, Maria Luisa Lozano, Nuria Bermejo, María Perera, Estefanía Bolaños, Luis F. Casado-Montero, Gonzalo Carreño-Tarragona, Elisa Orna-Montero, Manuel A. Rodríguez-López, Isidro Jarque, Tomás José González-López, David Valcárcel, Maria Eva Mingot-Castellano, Aurora de Andrés, Silvana Novelli, Rosa M. Campos-Alvarez, María Fernanda López-Fernández, María Teresa Álvarez-Román, Nuria Revilla, José Ramón González-Porras
Přispěvatelé: Institut Català de la Salut, [Lozano ML] Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CB15/00055-CIBERER, Murcia, Spain. [Mingot-Castellano ME] Hospital Carlos Haya, Málaga, Hospital Universitario Virgen del Rocio, Sevilla, Spain. [Perera MM] Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain. [Jarque I] Hospital Universitario y Politécnico La Fe, Valencia, Spain. [Campos-Alvarez RM] Hospital de Especialidades de Jerez de la Frontera, Cádiz, Spain. [González-López TJ] Hospital Universitario de Burgos, Burgos, Spain. [Valcarcel D] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
medicine.medical_treatment
lcsh:Medicine
Receptors
Fc
Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Benzoates
chemistry.chemical_compound
0302 clinical medicine
Trombocitopènia
hemic and lymphatic diseases
Young adult
lcsh:Science
Aged
80 and over
Multidisciplinary
Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Purpura::Purpura
Thrombocytopenic::Purpura
Thrombocytopenic
Idiopathic [DISEASES]
enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de la coagulación sanguínea::púrpura::púrpura trombocitopénica::púrpura trombocitopénica idiopática [ENFERMEDADES]
Middle Aged
Prognosis
Survival Rate
Hydrazines
Thrombopoietin
030220 oncology & carcinogenesis
Female
Receptors
Thrombopoietin
Haematological diseases
medicine.drug
Agonist
Adult
medicine.medical_specialty
medicine.drug_class
Recombinant Fusion Proteins
Splenectomy
Eltrombopag
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
Article
03 medical and health sciences
Young Adult
Internal medicine
medicine
Humans
Author Correction
Survival rate
Immunological disorders
Aged
Retrospective Studies
Thrombopoietin receptor
Purpura
Thrombocytopenic
Idiopathic
Romiplostim
business.industry
lcsh:R
Retrospective cohort study
chemistry
Pyrazoles
lcsh:Q
Medicaments - Administració
business
030215 immunology
Follow-Up Studies
Zdroj: Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
SCIENTIFIC REPORTS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
r-FISABIO. Repositorio Institucional de Producción Científica
Recercat. Dipósit de la Recerca de Catalunya
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
ISSN: 2045-2322
Popis: Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR). We conducted an observational, retrospective, long-term follow-up multicenter study from November 2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 2014. Data reflected that a platelet count ≤25 × 109/l at the time when the TPO-RA was initiated was associated with a 2.8 higher probability of receiving romiplostim vs. eltrombopag (P = 0.010). VE on TPO-RA was related to previous neoplasia in patients over 65 years (50% vs. 2.2%, P vs. 33%, P = 0.001). Receiving romiplostim as first TPO-RA with no subsequent TPO-RA switching was associated with a 50% likelihood of TFR after 2.9 years of therapy (3.3 years in chronic ITP patients). These real-world data help deciphering some areas of uncertainty, and offer insight into some of the most relevant challenges of ITP which may help clinicians make appropriate treatment decisions in the management of adult ITP patients with TPO-RA.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje